loading page

Effectiveness of Fractionated Rituximab in Preventing Tumor Lysis Syndrome in Aggressive B-Cell Lymphoma: Insights from Real-Life Clinical Practice
  • +6
  • Noémie Lang,
  • Jasmine Mohamad,
  • Antonin Bouroumeau,
  • Thomas McKee,
  • Nicolas Mach,
  • Kaveh Samii,
  • Martine Chamuleau,
  • Frank Stenner,
  • Jerome Tamburini
Noémie Lang
Universite de Geneve Section de medecine clinique

Corresponding Author:[email protected]

Author Profile
Jasmine Mohamad
Universite de Geneve Section de medecine clinique
Author Profile
Antonin Bouroumeau
Universite de Geneve Departement de pathologie et immunologie
Author Profile
Thomas McKee
Universite de Geneve Departement de pathologie et immunologie
Author Profile
Nicolas Mach
Hopitaux Universitaires Geneve Service d'oncologie
Author Profile
Kaveh Samii
Hopitaux Universitaires Geneve Departement d'Oncologie
Author Profile
Martine Chamuleau
Cancer Centre Amsterdam
Author Profile
Frank Stenner
Universitat Basel
Author Profile
Jerome Tamburini
Universite de Geneve Section de medecine clinique
Author Profile

Abstract

Tumor lysis syndrome (TLS) is a life-threatening condition caused by the rapid destruction of malignant cells, leading to imbalances in electrolytes and posing risks such as acute kidney injury, arrhythmia, and seizures. This retrospective study aimed to evaluate the incidence of TLS in a cohort of 94 patients with advanced-stage aggressive B-cell malignancies treated with fractionated rituximab, along with usual TLS preemptive measures such as hyperhydration and urate-lowering treatments. The study found that TLS occurred in seven patients, with one case classified as clinical TLS (cTLS) and six as laboratory TLS (lTLS). The incidence of TLS was higher in patients with Burkitt lymphoma compared to diffuse large B-cell lymphoma. TLS occurrence did not significantly influence survival outcomes in this cohort. Comparison with other datasets showed similar TLS rates in patients with high-grade B-cell lymphoma. These findings contribute to the understanding of TLS in B-cell malignancies, highlighting the potential of fractionated rituximab as a debulking approach to manage TLS risk that warrants further investigation in prospective trials.
06 Oct 2023Submitted to Cancer Reports
09 Oct 2023Submission Checks Completed
09 Oct 2023Assigned to Editor
09 Oct 2023Review(s) Completed, Editorial Evaluation Pending
10 Oct 2023Editorial Decision: Revise Major
01 Nov 20231st Revision Received
06 Nov 2023Submission Checks Completed
06 Nov 2023Assigned to Editor
06 Nov 2023Review(s) Completed, Editorial Evaluation Pending
09 Nov 2023Reviewer(s) Assigned